Kyron.bio key facts
as of Oct 2026- Operator of a bioproduction platform intended to produce cheap and novel biopharmaceuticals.
- Kyron.bio is valued at approximately $15.0M as of Oct 2026 (last reported valuation).
- It has raised $8.1M; the latest was Seed Round ($6.2M) in May 2025.
- Notable investors include Creative Destruction Lab, Bpifrance, European Innovation Council, Entrepreneurs First, European Commission — 13 tracked in total.
- Status: Privately Held (backing).
Kyron.bio's last reported valuation, May 2025. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch Kyron.bio: the Monday email on marks, rounds and moves
Kyron.bio funding rounds
No funding rounds for Kyron.bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Kyron.bio
13+Kyron.bio valuation
Kyron.bio's last reported valuation was $15 million in May 2025. No priced round, secondary trade or fund mark has surfaced since.
Kyron.bio investors
13 investors are on record for Kyron.bio, including Creative Destruction Lab, Bpifrance, European Innovation Council and Entrepreneurs First. By type, the record holds 4 venture capital firms and 1 hedge fund.
About Kyron.bio
Operator of a bioproduction platform intended to produce cheap and novel biopharmaceuticals. The company's platform leverages patentable technology that boosts the effectiveness and yield of therapeutic proteins produced in mammalian cell factories by harnessing efficient processes from diverse organisms to precisely control the glycosylation pattern on the surface of a biologic for developing medicines, enabling the bioproduction industry to revolutionize drug production.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2022
- Employees
- 7
- Website
- kyron.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.